L2 radiation oncology:
	- four Rs:
		- repair: sublethal damage to cells between doses
		- redistribution: cells -> radiosensitive phases
		- reoxygenation: of hypoxic cells -> more sensitive to radiation
		- repopulation: regrowth of cells between doses

	- radiation side effects:
		- swelling, redness
		- so many


L3 breast cancer: 
	- epideiomiology:
		 - 1/8 women
	- risks:
		- nulliparity / birth age > 30
		- estrogen exposure
		- radiation
		- syndromes:
			- li fraumeni
			- cowden syndrome (PTEN)
			- BRCA1/2
				- breast cancer: 40-80% lifetime risk
				- ovarian cancer: 20-40% lifetime risk
	
	- breast anatomy:
		- terminal duct lobular unit
	
	- benign:
		- fibrocystic changes
		- fibroadenoma
		- breast cysts
		- fat necrosis
		- galactocele

	- proliferative with atype (RR 5x):
		- atypical ductal hyperplasia (ADH):
			- pathology: atypical duct wall cells
		- atypical lobular hyperplasia (ALH)

	- carcinoma in situ (RR 10x):
		- stage 0
		- lobular carcinoma in situ (LCIS):
			- pathology: small cells in lobules
			- multifocal + bilateral

		- ductal carcinoma in situ (DCIS):
			- pathology: looks like muscle/fibrosis around duct
			- 25% of breast cancers
			- ipsilateral risk

	- invasive carcinomas:
		- ductal:
			- pathology: irregular nests w/o peripheral myoepithelial cells
		- lobular:
			- pathology:
				- linear growth (single file)
				- E-cadherin negative: cells don't stick together

	- screening: 
		- yearly 45-54 yo -> at 55: every other year
		- 40-44 counseling on option for screening
	
	- primary prevention:
		- BRCA1/2: mastectomy + oophorectomy
		- tx: tamoxifen (SERM) + aromatase inhibitor
		- prevent BC: "Think Aromatase": T + AI

	- dx:
		- mammogram, if <30: US, maybe MRI
		- microcalcifications: DCIS
		- metastatic: CT, bone scan

	- prognosis:
		- worse:
			- size, stage, grade, proliferation
			- ER- (<1%)
			- PR- (<1%)
			- HER-2 positive (IHC 3+)
			- high oncotype Dx:
				- high risk: chemo beneficial

	- tx:
		- surgery:
			- mastetomy vs lumpectomy
			- sentinel node vs axillary node biopsy
		- radiation:
			- if lumpectomy
			- if mastectomy + large tumor or node involvement
		
		- systemic:
			- everything: chemotherapy:
				- regimen:
					- doxorubicin
					- cyclophosphamide
					- taxanes
					- CDT
			
			- anti-HER2+: trastuzumab/pertuzumab x 1yr
			- HR+/PR+: tamoxifen or aromatase inhibitor x 5-10 years

		- post-treatment:
			- regular mammograms, physicals
			- no scans/biomarkers if asymptomatic
			- BRAC1/2:
				- give PARPi

	- metastatic tx:
		- ER+/PR+:
			- aromatase inhibitors
			- CDK 4/6 inhibitors
		- HER2+:
			- chemo
			- anti-HER2: trastuzumab/pertuzumab
			- ADC: T-Dxd
		- triple negative:
			- chemo + anti-PD1

		- general metastatic:
			- sacituzimab govitecan

		- supportive: bisphosphonates / denosumab

	- pathology:
		- ductal:
		- lobular:

			 


L7 lung cancer:
	- NSCLC:
		- tx:
			- chemo:
				- platinums: cisplatin, carboplatin
				- taxanes
				- gemcitabine
				- Tobacco Promotes Growth -> TPG -> Taxanes + Platinums + Gemcitabine
			- anti-PD1
			- EGFR inhibitors: osimertinib, erlotinib
			- ALK + RET inhibitor: alectinib
			- BRAF V600E inhibitors: dabrafenib + trametinib
			- KRAS: sotorasib
			- HER2 mutation: TdX-T

	- SCLC:
		- tx:
			- chemo: platinum + etoposide
				- small cell -> small PE -> Platinum + Etoposide
			- radiation:
				- concurrent w/ chemo
				- prophylactic cranial irradiation (PCI)

L10 colorectal cancer:
	- tx:
		- chemo:
			- colon cancer: FOLFOX -> Fluorouracil + Oxaliplatin
			- rectal cancer: radiation + capecitabine -> adjuvant oxaliplatin
	- metastatic tx: chemo + targetted
		- chemo: FOLFOX
		- targeted:
			- anti-VEGF: bevacizumab
			- anti-EFGR: cetuximab - only in RAS WT
		- MSI high: anti-PD1


L15 oncology rounds I:
	- bladder cancer:
		- tx:
			- bacillus calmette-guerin (BCG)
			- mitomycin
	- melanoma:
		- anti-PD1
		- BRAF V600E: BRAFi + MEKi
	- head + neck: no tx given
	- gastric: amoxicillin for H. pylori


L16 oncology rounds II:
	- ovarian cancer:
		- tx:
			- chemo:
				- platinums + taxanes: carboplatin + paclitaxel
	- liver cancer:
		- tx: resection/transplant
	- pancreatic cancer:
		- tx:
			- surgery
			- chemo: gemcitabine + 5FU

	- renal cell carinoma:
		- tx:
			- sunitinib/pazopanib
			- anti-PD1
			- anti-VEGF: bevacizumab


L17 oncology rounds III:
	- ewing's sarcoma:
		- tx:
			- cyclophosphamide + doxorubicin + vincristine
			- ifosfamide + etoposide
			- COD EIght: Cyclophosphamide + Ovincristine + Doxorubicin

	- gastrointestinal stromal tumor (GIST):
		- tx:
			- surgery
			- targeted: imatinib for cKIT

	- testicular cancer:
		- tx:
			- surgery: orchiectomy
			- chemo:
				- cisplatin
				- bleomycin
				- etoposide
				- EBC: Expell Ball Cancer - Etoposide + Bleomycin + Cisplatin






L12: prostate cancer
	main:
	- epidiomiology:
		- most common male cancer (27%)
		- 2nd most common male cancer death (11%)
		- 11% lifetime risk
		- 3% lifetime death risk
		- median age 66
		- most common 65-74 ages
	- risk factors:
		- familial risks (2x per first degree relative)
		- BRCA: 1 -> 2x, 2->5x

	- screening:
		- prostate specific antigen (PSA)
			- glycoprotein: liquefys semen
			- cutoff: 4 ng/ml
				- sens: 21%, 51% for gleason >= 8
				- spec: 91%
			- false positives: BPH, prostatitis, ejaculation, urinary retention
		- controversial, only test 55-69
	
	- histology:
		- prostate:
			- lobular glands + ducts
				- basal layer: cubuoidal
				- luminal cells: columnar secretory
			- fibromuscular stroma around glands
		- gleason grading:
			- higher worse
			- add 1st and 2nd cell population scores
			- grading:
				- 3: lots of glands, differing sizes
				- 4: glands fuse, no lumens
				- 5: no gland differentiation
			
			- risk:
				- <=6: low risk
				- 7: medium risk
				- >=8+: high risk

	- pathology:
		- adenocarcinomas:
			- occur in peripheral zone
			- infiltrative, crowded glands
			- large nuclei + nucleoli
			- basal cell layer missing

		- benign prostatic hyperplasia:
			- 20% men at 40
			- 70% men at 60
			- partial or complete urethral obstruction
			- only in transitional zone: around urethral start by bladder

	- symptoms:
		- 80% asymptomatic
		- 20%: urinary frequency, urgency, nocturia, hematuria, bone pain

	- biopsy: 12 cores, transrectal US guided
	
	- treatment:
		- localized:
			- surgery (prostatectomy):
				- risks:
					- ED - 43% at 2 years
					- incontinence: 15% at 2 years
			- radiation:
				- risks similar to surgery
				- external beam:
					- low risk for incontinence
				- brachytherapy: radioactive seeds
			- active surveillance:
				- less risks, but similar to surgery
				- PSA every 3 mo
		
		- metastatic:
			- hormonal therapy:
				- androgen deprivation therapy (ADT):
					- goal: testosterone < 50 ng/ml
					- GnRH agonists: goserelin, leuprolide
					- antiandrogen: bicalutamide
						- initial GnRH androgen flare
				- orchiectomy:
					- quick, cost effective

			- castrate resistant prostate cancer (CRPC):
				- prostate cancer -> CRPC after ~2 years of ADT
				- metastatic lethal form
				- tx:
					- chemo: docetaxel
					- hormonal:
						- abitarone + prednisone
						- enzaulatamide
					- immune: car-T - sipuleucel-T
					- radium 223: targets bone mets
				
				- supportive care (for bone mets):
					- zoledronic acid (bisphosphonates)
						- inhibits Ca release from tumors
					- denosumab: